Equillium grants 800,000 stock options to new hires under Nasdaq inducement rule.

Equillium, a biotech company, granted 800,000 nonstatutory stock options to two new employees as inducement awards under its 2024 Inducement Plan. The options, priced at $2.08 each (the stock's closing price on May 1, 2026), will vest over four years, encouraging employee retention. This move complies with Nasdaq Listing Rule 5635(c)(4) and aims to attract key talent to support Equillium's development of therapies for autoimmune and inflammatory disorders. The company’s lead drug candidate, EQ504, targets diseases like ulcerative colitis and inflammatory lung conditions.